Solana Company (NASDAQ:HSDT) Short Interest Up 71.1% in December

Solana Company (NASDAQ:HSDT) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totaling 963,146 shares, a growth of 71.1% from the December 15th total of 562,864 shares. Based on an average daily volume of 633,610 shares, the days-to-cover ratio is currently 1.5 days. Approximately 2.8% of the shares of the stock are sold short. Approximately 2.8% of the shares of the stock are sold short. Based on an average daily volume of 633,610 shares, the days-to-cover ratio is currently 1.5 days.

Solana Stock Up 6.5%

Shares of NASDAQ HSDT traded up $0.20 during midday trading on Friday, reaching $3.30. 218,558 shares of the stock traded hands, compared to its average volume of 503,491. The company’s 50 day moving average is $3.56 and its 200 day moving average is $7.43. Solana has a one year low of $2.62 and a one year high of $1,200.00.

Solana (NASDAQ:HSDT) last released its quarterly earnings results on Tuesday, November 18th. The company reported ($32.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($50.50) by $17.61. Solana had a negative net margin of 39,358.88% and a negative return on equity of 699.93%. The company had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.11 million.

Analyst Upgrades and Downgrades

HSDT has been the topic of a number of research analyst reports. Wall Street Zen raised Solana from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of Solana in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Solana stock. Grant Private Wealth Management Inc acquired a new position in shares of Solana Company (NASDAQ:HSDT) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 15,805 shares of the company’s stock, valued at approximately $46,000. 18.63% of the stock is currently owned by institutional investors and hedge funds.

About Solana

Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.